title: Topoisomerase II-alpha expression in melanocytic nevi and malignant melanoma.
abstract: Malignant melanoma (MM) is considered to be a chemotherapy-refractory tumor. New anti-cancer drugs (e.g. etoposide) that target DNA topoisomerases (e.g. topoisomerase II-alpha (topo IIalpha)) show activity against a wide variety of solid tumors. In this study, we investigated the frequency and rate of labeling for topo IIalpha in 163 MMs (primary and metastatic) and 67 melanocytic nevi to determine whether topo IIalpha expression is elevated in MM. Primary MM exhibited significantly more frequent topo IIalpha expression compared to benign nevi (86% vs. 56%, p=0.0001). The rate of topo IIalpha labeling in dysplastic melanocytic nevi, radial growth phase MM, vertical growth phase MM and metastatic MM revealed significant differences amongst groups and a positive covariance with advancing stage (means: 0.3, 0.5, 5, and 8 '+' cells/hpf, respectively; r=0.3, all p < or = 0.02). Topo IIalpha labeling significantly correlated with increasing mitotic activity, depth of invasion and Clark's level, diminishing tumor infiltrating lymphocytes, and poor outcome (all p < or = 0.01) in primary MM. For metastatic MM, a minority (30%) exhibited marked elevation of topo IIalpha expression. These findings indicate topo IIalpha as a potential therapeutic target and marker for MM. Immunohistochemical analysis of disseminated MM may allow for correlation with clinical response and enable selection of candidates sensitive for specific chemotherapy.
authors.affiliation: Division of Dermatopathology and Dermatology, Samuel S. Stratton Veteran Administration Medical Center and Albany Medical College, New York 12208, USA.
authors.forename: X C
authors.initials: XC
authors.lastname: Mu
authors.forename: T A
authors.initials: TA
authors.lastname: Tran
authors.forename: J S
authors.initials: JS
authors.lastname: Ross
authors.forename: J A
authors.initials: JA
authors.lastname: Carlson
mesh_terms: D000951:Antigens, Neoplasm / Q000378:metabolism*; D004250:DNA Topoisomerases, Type II / Q000378:metabolism*; D004268:DNA-Binding Proteins; D019085:Fluorescent Antibody Technique, Direct; D006801:Humans; D007527:Isoenzymes / Q000378:metabolism*; D016246:Lymphocytes, Tumor-Infiltrating / Q000473:pathology; D008545:Melanoma / Q000201:enzymology* / Q000401:mortality / Q000556:secondary; D008940:Mitotic Index; D009361:Neoplasm Invasiveness / Q000473:pathology; D009508:Nevus, Pigmented / Q000201:enzymology* / Q000473:pathology; D011379:Prognosis; D012878:Skin Neoplasms / Q000201:enzymology* / Q000401:mortality / Q000473:pathology; D016019:Survival Analysis; D015996:Survival Rate
chemical_list: D000951:Antigens, Neoplasm; D004268:DNA-Binding Proteins; D007527:Isoenzymes; D004250:DNA Topoisomerases, Type II